Formosa Pharmaceuticals
0
0
+TWD0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Financials
-880.09%Profit Margin
Unprofitable9.5MRevenue
-83.57MNet Income
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing TSY-110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer. It has a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutic. Formosa Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Taipei City, Taiwan.
Show More
CEO
ISIN
TW0006838006
Listings
0 Comments
Share your thoughts
FAQs
What is Formosa Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Taiwan OTC Exchange exchange Formosa Pharmaceuticals stocks are traded under the ticker 6838.TWO.
What is Formosa Pharmaceuticals revenue for the last year?▼
Formosa Pharmaceuticals revenue for the last year amounts to 9.5M TWD.
What is Formosa Pharmaceuticals net income for the last year?▼
6838.TWO net income for the last year is -83.57M TWD.
In which sector is Formosa Pharmaceuticals located?▼
Formosa Pharmaceuticals operates in the Other sector.
When did Formosa Pharmaceuticals complete a stock split?▼
Formosa Pharmaceuticals has not had any recent stock splits.